Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) shows significant upside potential with a mean price target of $24.71, indicating a 386.4% increase from the current price of $5.08 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $18 to a high of $30, with a standard deviation of $4.64, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 254.3%, while the highest suggests a 490.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about OLMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.4%, with five estimates moving higher and no negative revisions [12] Zacks Rank - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $10.65, gaining 35.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.05 indicates a 41.3% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.74. While the lowest estimate of $14.20 indicates a 33.3% increase from the current price level, the most optim ...

Oportun Financial Corporation (OPRT) closed the last trading session at $6.90, gaining 57.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.04 indicates a 31% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $1.70. While the lowest estimate of $6.50 indicates a 5.8% decline from the current price level, the most optimistic ...

One of the most powerful catalysts for any stock is a substantial change in a researcher's price target. That was the dynamic behind the more than 2% gain of European Wax Center (EWCZ 1.94%) on Monday, as an analyst tracking the stock significantly upped her fair value assessment. The stock's rise far outpaced the less than 0.1% increase of the S&P 500 index that day. A 33% price target hikeWell before market open, Citigroup's Kelly Crago made the move. She upped her European Wax Center price target to $6 p ...

Core Viewpoint - Backblaze, Inc. (BLZE) shares have increased by 13.4% in the past four weeks, closing at $5.32, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $10.83, representing a 103.6% upside [1] Price Targets - The average price targets from analysts range from a low of $8 to a high of $14, with a standard deviation of $1.94, indicating variability in estimates; the lowest estimate suggests a 50.4% increase, while the highest points to a 163.2% upside [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates - Analysts have shown increasing optimism about BLZE's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.3% over the past month, with four estimates increasing and no negative revisions [12] Zacks Rank - BLZE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential upside in the near term [13]

Core Viewpoint - SkyWater Technology, Inc. (SKYT) shows significant potential for upside, with a mean price target of $11 indicating a 35% upside from its current price of $8.15, following a 23.7% gain over the past four weeks [1]. Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $8 to a high of $12, with a standard deviation of $1.73, indicating variability in estimates. The lowest estimate suggests a decline of 1.8%, while the highest points to a 47.2% upside [2]. - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding SKYT's earnings prospects, as indicated by a positive trend in earnings estimate revisions. This trend has a strong correlation with near-term stock price movements [11]. - Over the last 30 days, two earnings estimates for SKYT have been revised upward, leading to a 20.8% increase in the Zacks Consensus Estimate [12]. Zacks Rank and Investment Potential - SKYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, which further supports its potential for upside [13].

Core Viewpoint - JD.com's recent first-quarter results were generally well-received, but an analyst's price target cut led to a nearly 4% decline in stock price [1] Group 1: Analyst's Price Target Adjustment - Susquehanna International's Shyam Patil reduced JD.com's price target by over 10%, from $45 to $40 per share, while maintaining a neutral recommendation [2] - Despite the price target cut, Patil did not change his overall estimation of the stock [2] Group 2: Company Performance and Market Position - Patil praised JD.com's first-quarter performance, noting improvements in user experience that are driving user growth [4] - The company is well-positioned in the market and could benefit from expansion into new segments like food delivery [4] Group 3: Economic Concerns - The shaky state of the Chinese economy may limit JD.com's potential, according to Patil [5] - This economic uncertainty is expected to persist, influencing the analyst's price target reduction and neutral outlook [5] Group 4: Growth Potential - JD.com demonstrated encouraging year-over-year growth, particularly in its bottom line, and exceeded consensus analyst estimates [6] - There are indications that the Chinese macroeconomy might be in better shape than perceived, suggesting that JD.com should not be underestimated if it continues to improve its fundamentals [7]

Inspired Entertainment (INSE) closed the last trading session at $8.17, gaining 12.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.40 indicates a 51.8% upside potential.The average comprises five short-term price targets ranging from a low of $10 to a high of $16, with a standard deviation of $2.30. While the lowest estimate indicates an increase of 22.4% from the current pr ...

Encore Capital Group (ECPG) closed the last trading session at $40.51, gaining 38.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $58.50 indicates a 44.4% upside potential.The average comprises four short-term price targets ranging from a low of $55 to a high of $66, with a standard deviation of $5.07. While the lowest estimate indicates an increase of 35.8% from the current pri ...

Shares of Altimmune, Inc. (ALT) have gained 39.4% over the past four weeks to close the last trading session at $5.80, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $22.38 indicates a potential upside of 285.9%.The mean estimate comprises eight short-term price targets with a standard deviation of $5.32. While the lowest estimate of $12 indicates a 106.9% increase from the cur ...